Semaglutide vs Tirzepatide
Compare Semaglutide and Tirzepatide, two leading GLP-1 receptor agonists used in metabolic research. Explore their differences in receptor targets, half-life, dosing, and research applications.
Semaglutide
GLP-1 / Weight Management
Tirzepatide
GLP-1 / Weight Management
Comparación Lado a Lado
GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release
Dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously for synergistic metabolic effects
GLP-1 receptor only
GIP receptor + GLP-1 receptor (dual agonist)
~7 days (enabling once-weekly dosing)
~5 days (once-weekly dosing)
Once weekly
Once weekly
Type 2 diabetes glycemic control, obesity and weight management, cardiovascular risk reduction, NASH/fatty liver disease, appetite regulation
Type 2 diabetes with superior HbA1c reduction, obesity with significant weight loss, dual incretin pharmacology, cardiovascular and metabolic syndrome research
4113.64 Da
4813.45 Da
$14.95/vial (2mg)
$14.95/vial (2mg)
GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release
Dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously for synergistic metabolic effects
GLP-1 receptor only
GIP receptor + GLP-1 receptor (dual agonist)
~7 days (enabling once-weekly dosing)
~5 days (once-weekly dosing)
Once weekly
Once weekly
Type 2 diabetes glycemic control, obesity and weight management, cardiovascular risk reduction, NASH/fatty liver disease, appetite regulation
Type 2 diabetes with superior HbA1c reduction, obesity with significant weight loss, dual incretin pharmacology, cardiovascular and metabolic syndrome research
4113.64 Da
4813.45 Da
$14.95/vial (2mg)
$14.95/vial (2mg)
¿Cuál es el Adecuado para tu Investigación?
Choose Semaglutide for established single-receptor GLP-1 research with the longest half-life in its class. Choose Tirzepatide when studying dual incretin pathway synergy for potentially greater metabolic effects.